🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07676383
Recruiting Not applicable

Precision Navigation to Improve Community Cancer Screening Participation

NCT07676383 · tracked via the Priya Life Science China tracker
Sponsor
Hunan Cancer Hospital
Phase
Not applicable
Started
2026-08-04
Last updated
2026-09-18

Condition(s) studied

Cancer ScreeningLung CancerBreast CancerColorectal CancerUpper Gastrointestinal CancerLiver Cancer

Investigational drug(s) / intervention(s)

Precision Navigation InterventionUsual Health Education

Precision Navigation Intervention: Participants in the precision navigation group will receive a personalized navigation report based on their cancer risk profile from the urban cancer screening program. The report will be tailored according to whether the participant is at high risk for three or more cancers or for one or two cancers. It will provide individualized information on high-risk cancer types, recommended screening tests, screening procedures, common barriers to screening, and practical action steps. Trained staff will provide a brief standardized explanation of the report and support participants in making a screening action plan.

Usual Health Education: Participants in the usual health education group will receive general cancer screening education materials. The materials will provide basic information about cancer prevention, early detection, and screening for lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, and liver cancer. The content is not personalized according to the participant's individual risk profile.

Study summary

This study will evaluate whether a precision navigation intervention can help community residents at high risk for cancer complete recommended cancer screening. The study will be conducted in communities participating in an urban cancer screening program in China.

Eligible participants will be adults aged 45 to 74 years who are permanent residents of participating communities and have been identified as being at high risk for at least one of five cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer. Participants must not have completed the corresponding free clinical screening before enrollment.

This is a dual-cohort, cluster randomized controlled trial. Communities, rather than individual participants, will be assigned to one of three groups: a precision navigation group, a usual health education group, or a waiting control group. Participants will be classified into two cohorts according to the number of cancers for which they are assessed as high risk. Cohort A will include participants at high risk for three or more cancers, and Cohort B will include participants at high risk for one or two cancers.

Participants in the precision navigation group will receive a personalized navigation report matched to their risk profile. The report will explain the screening tests most relevant to them, help them understand screening choices, and provide practical steps to support screening completion. Participants in the usual health education group will receive general cancer screening education materials. Participants in the waiting control group will not receive active screening promotion during the main intervention period, but will receive general education materials after the primary assessment.

The main outcome is whether participants complete the recommended cancer screening during follow-up. The study will also assess changes in screening-related decision conflict, anxiety, self-efficacy, and behavioral intention.

The results may help improve community-based cancer screening programs and provide evidence for using personalized navigation strategies to increase screening participation among high-risk populations.

Eligibility

Sex
ALL
Min age
45 Years
Max age
74 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Aged 45 to 74 years. 2. Permanent resident of a participating community, defined as having lived in the community for at least 6 months during the past 12 months. 3. Participating in the urban cancer screening program. 4. Identified by the program risk assessment questionnaire as being at high risk for at least one of the following cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer. 5. Has not yet completed the corresponding free clinical screening test for the high-risk cancer type or types. 6. Able to complete electronic questionnaires and read intervention materials independently or with assistance. Paper materials and staff explanation will be provided for participants who do not use smartphones. 7. Able and willing to provide written informed consent. Exclusion Criteria: 1. Previously diagnosed with any of the target cancers, including lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer. 2. Severe cognitive impairment, severe mental illness, or other conditions that prevent the participant from receiving the intervention or completing study questionnaires. 3. Planning to be away from the community for a long period during the next 6 months, defined as cumulative absence of more than 3 months. 4. Currently participating in another interventional study that may affect cancer screening behavior.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Huaihua Central Hospital (Huaihua Cancer Hospital) Huaihua Hunan Recruiting
Shaoyang Hospital of Traditional Chinese Medicine Shaoyang Hunan Recruiting
Yongzhou Central Hospital Yongzhou Hunan Recruiting

More Hunan Cancer Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07676383 on ClinicalTrials.gov ↗ ← All trials in China